Neuropilin signalling in vessels, neurons and tumours

Seminars in Cell and Developmental Biology

Volumn 24, Issue 3, 2013, Pages 172-178

  Raimondi, Claudio ^a   Ruhrberg, Christiana ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Angiogenesis; Cancer; Neural crest cell; Neuron; Neuropilin; Semaphorin; VEGF

Indexed keywords

NEUROPILIN; NEUROPILIN 1; NEUROPILIN 2; VASCULOTROPIN A; VASCULOTROPIN C;

CENTRAL NERVOUS SYSTEM; ENDOTHELIUM; HUMAN; LYMPH VESSEL; NEOPLASM; NERVE CELL; NEURAL CREST CELL; NONHUMAN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SYNAPTOGENESIS;

EID: 84875631991     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2013.01.001     Document Type: Review

References (109)

1. Adams R.H., Eichmann A. Axon guidance molecules in vascular patterning. Cold Spring Harbor Perspectives in Biology 2010, 2:a001875.
2. Mackenzie F., Ruhrberg C. Diverse roles for VEGF-A in the nervous system. Development 2012, 139:1371-1380.
3. Schwarz Q., Ruhrberg C. Neuropilin, you gotta let me know: should I stay or should I go?. Cell Adhesion & Migration 2010, 4:61-66.
4. Mamluk R., Gechtman Z., Kutcher M.E., Gasiunas N., Gallagher J., Klagsbrun M. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. The Journal of Biological Chemistry 2002, 277:24818-24825.
5. Gu C., Limberg B.J., Whitaker G.B., Perman B., Leahy D.J., Rosenbaum J.S., et al. Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. The Journal of Biological Chemistry 2002, 277:18069-18076.
6. Nakamura F., Kalb R.G., Strittmatter S.M. Molecular basis of semaphorin-mediated axon guidance. Journal of Neurobiology 2000, 44:219-229.
7. Gu C., Rodriguez E.R., Reimert D.V., Shu T., Fritzsch B., Richards L.J., et al. Neuropilin-1 conveys semaphorin and VEGF signaling during neural and cardiovascular development. Developmental Cell 2003, 5:45-57.
8. Kawasaki T., Kitsukawa T., Bekku Y., Matsuda Y., Sanbo M., Yagi T., et al. A requirement for neuropilin-1 in embryonic vessel formation. Development 1999, 126:4895-4902.
9. Bouvree K., Brunet I., Del Toro R., Gordon E., Prahst C., Cristofaro B., et al. Semaphorin3A, Neuropilin-1, and PlexinA1 are required for lymphatic valve formation. Circulation Research 2012, 111:437-445.
10. Yuan L., Moyon D., Pardanaud L., Breant C., Karkkainen M.J., Alitalo K., et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 2002, 129:4797-4806.
11. Ribatti D., Judah Folkman A pioneer in the study of angiogenesis. Angiogenesis 2008, 11:3-10.
12. Nissen N.N., Polverini P.J., Koch A.E., Volin M.V., Gamelli R.L., DiPietro L.A. Vascular endothelial growth factor mediates angiogenic activity during the proliferative phase of wound healing. The American Journal of Pathology 1998, 152:1445-1452.
13. Saint-Geniez M., D'Amore P.A. Development and pathology of the hyaloid, choroidal and retinal vasculature. The International Journal of Developmental Biology 2004, 48:1045-1058.
14. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Reviews Cancer 2008, 8:579-591.
15. Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochemical Journal 2011, 437:169-183.
16. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J.C., et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. The Journal of Biological Chemistry 1991, 266:11947-11954.
17. Park J.E., Keller G.A., Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Molecular Biology of the Cell 1993, 4:1317-1326.
18. Houck K.A., Leung D.W., Rowland A.M., Winer J., Ferrara N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. The Journal of Biological Chemistry 1992, 267:26031-26037.
19. Ruhrberg C., Gerhardt H., Golding M., Watson R., Ioannidou S., Fujisawa H., et al. Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis. Genes & Development 2002, 16:2684-2698.
20. Vintonenko N., Pelaez-Garavito I., Buteau-Lozano H., Toullec A., Lidereau R., Perret G.Y., et al. Overexpression of VEGF189 in breast cancer cells induces apoptosis via NRP1 under stress conditions. Cell Adhesion & Migration 2011, 5:332-343.
21. Parker M.W., Xu P., Li X., Vander Kooi C.W. Structural basis for selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1. The Journal of Biological Chemistry 2012, 287:11082-11089.
22. Schwarz Q., Gu C., Fujisawa H., Sabelko K., Gertsenstein M., Nagy A., et al. Vascular endothelial growth factor controls neuronal migration and cooperates with Sema3A to pattern distinct compartments of the facial nerve. Genes & Development 2004, 18:2822-2834.
23. Erskine L., Reijntjes S., Pratt T., Denti L., Schwarz Q., Vieira J.M., et al. VEGF signaling through neuropilin 1 guides commissural axon crossing at the optic chiasm. Neuron 2011, 70:951-965.
24. Cariboni A., Davidson K., Dozio E., Memi F., Schwarz Q., Stossi F., et al. VEGF signalling controls GnRH neuron survival via NRP1 independently of KDR and blood vessels. Development 2011, 138:3723-3733.
25. Gluzman-Poltorak Z., Cohen T., Herzog Y., Neufeld G. Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165. The Journal of Biological Chemistry 2000, 275:18040-18045.
26. Prahst C., Heroult M., Lanahan A.A., Uziel N., Kessler O., Shraga-Heled N., et al. Neuropilin-1-VEGFR-2 complexing requires the PDZ-binding domain of neuropilin-1. The Journal of Biological Chemistry 2008, 283:25110-25114.
27. Soker S., Takashima S., Miao H.Q., Neufeld G., Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92:735-745.
28. Becker P.M., Waltenberger J., Yachechko R., Mirzapoiazova T., Sham J.S., Lee C.G., et al. Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability. Circulation Research 2005, 96:1257-1265.
29. Stacker S.A., Vitali A., Caesar C., Domagala T., Groenen L.C., Nice E., et al. A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability. The Journal of Biological Chemistry 1999, 274:34884-34892.
30. Wang L., Dutta S.K., Kojima T., Xu X., Khosravi-Far R., Ekker S.C., et al. Neuropilin-1 modulates p53/caspases axis to promote endothelial cell survival. PLoS ONE 2007, 2:e1161.
31. Evans I.M., Yamaji M., Britton G., Pellet-Many C., Lockie C., Zachary I.C., et al. Neuropilin-1 signaling through p130Cas tyrosine phosphorylation is essential for growth factor-dependent migration of glioma and endothelial cells. Molecular and Cellular Biology 2011, 31:1174-1185.
32. Wang L., Mukhopadhyay D., Xu X. C terminus of RGS-GAIP-interacting protein conveys neuropilin-1-mediated signaling during angiogenesis. FASEB Journal 2006, 20:1513-1515.
33. Fantin A., Schwarz Q., Davidson K., Normando E.M., Denti L., Ruhrberg C. The cytoplasmic domain of neuropilin 1 is dispensable for angiogenesis, but promotes the spatial separation of retinal arteries and veins. Development 2011, 138:4185-4191.
34. Haigh J.J., Gerber H.P., Ferrara N., Wagner E.F. Conditional inactivation of VEGF-A in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development 2000, 127:1445-1453.
35. Herzog Y., Kalcheim C., Kahane N., Reshef R., Neufeld G. Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mechanisms of Development 2001, 109:115-119.
36. Xu Y., Yuan L., Mak J., Pardanaud L., Caunt M., Kasman I., et al. Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. The Journal of Cell Biology 2010, 188:115-130.
37. Karpanen T., Heckman C.A., Keskitalo S., Jeltsch M., Ollila H., Neufeld G., et al. Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. FASEB Journal 2006, 20:1462-1472.
38. Favier B., Alam A., Barron P., Bonnin J., Laboudie P., Fons P., et al. Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood 2006, 108:1243-1250.
39. Gluzman-Poltorak Z., Cohen T., Shibuya M., Neufeld G. Vascular endothelial growth factor receptor-1 and neuropilin-2 form complexes. The Journal of Biological Chemistry 2001, 276:18688-18694.
40. Schwarz Q., Waimey K.E., Golding M., Takamatsu H., Kumanogoh A., Fujisawa H., et al. Plexin A3 and plexin A4 convey semaphorin signals during facial nerve development. Developmental Biology 2008, 324:1-9.
41. Ruiz de Almodovar C., Coulon C., Salin P.A., Knevels E., Chounlamountri N., Poesen K., et al. Matrix-binding vascular endothelial growth factor (VEGF) isoforms guide granule cell migration in the cerebellum via VEGF receptor Flk1. The Journal of Neuroscience 2010, 30:15052-15066.
42. Ruiz de Almodovar C., Fabre P.J., Knevels E., Coulon C., Segura I., Haddick P.C., et al. VEGF mediates commissural axon chemoattraction through its receptor Flk1. Neuron 2011, 70:966-978.
43. Cariboni A., Davidson K., Rakic S., Maggi R., Parnavelas J.G., Ruhrberg C. Defective gonadotropin-releasing hormone neuron migration in mice lacking SEMA3A signalling through NRP1 and NRP2: implications for the aetiology of hypogonadotropic hypogonadism. Human Molecular Genetics 2011, 20:336-344.
44. Hanchate N.K., Giacobini P., Lhuillier P., Parkash J., Espy C., Fouveaut C., et al. SEMA3A, a gene involved in axonal pathfinding, is mutated in patients with Kallmann syndrome. PLoS Genetics 2012, 8:e1002896.
45. Siebold C., Jones E.Y. Structural insights into semaphorins and their receptors. Seminars in Cell & Developmental Biology 2012.
46. Sakurai A., Doci C.L., Gutkind J.S. Semaphorin signaling in angiogenesis, lymphangiogenesis and cancer. Cell Research 2012, 22:23-32.
47. Tran T.S., Kolodkin A.L., Bharadwaj R. Semaphorin regulation of cellular morphology. Annual Reviews in Cell and Developmental Biology 2007, 23:263-292.
48. Baudet M.L., Bellon A., Holt C.E. Role of microRNAs in semaphorin function and neural circuit formation. Seminars in Cell & Developmental Biology 2012.
49. Oh W.J., Gu C. The role and mechanism-of-action of Sema3E and Plexin-D1 in vascular and neural development. Seminars in Cell & Developmental Biology 2012.
50. Luo Y., Raible D., Raper J.A. Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones. Cell 1993, 75:217-227.
51. Taniguchi M., Yuasa S., Fujisawa H., Naruse I., Saga S., Mishina M., et al. Disruption of semaphorin III/D gene causes severe abnormality in peripheral nerve projection. Neuron 1997, 19:519-530.
52. Vieira J.M., Schwarz Q., Ruhrberg C. Selective requirements for NRP1 ligands during neurovascular patterning. Development 2007, 134:1833-1843.
53. Schwarting G.A., Kostek C., Ahmad N., Dibble C., Pays L., Puschel A.W. Semaphorin 3A is required for guidance of olfactory axons in mice. The Journal of Neuroscience 2000, 20:7691-7697.
54. Kawasaki T., Bekku Y., Suto F., Kitsukawa T., Taniguchi M., Nagatsu I., et al. Requirement of neuropilin 1-mediated Sema3A signals in patterning of the sympathetic nervous system. Development 2002, 129:671-680.
55. Chen H., Bagri A., Zupicich J.A., Zou Y., Stoeckli E., Pleasure S.J., et al. Neuropilin-2 regulates the development of selective cranial and sensory nerves and hippocampal mossy fiber projections. Neuron 2000, 25:43-56.
56. Huber A.B., Kania A., Tran T.S., Gu C., De Marco Garcia N., Lieberam I., et al. Distinct roles for secreted semaphorin signaling in spinal motor axon guidance. Neuron 2005, 48:949-964.
57. Polleux F., Giger R.J., Ginty D.D., Kolodkin A.L., Ghosh A. Patterning of cortical efferent projections by semaphorin-neuropilin interactions. Science 1998, 282:1904-1906.
58. Tillo M., Ruhrberg C., Mackenzie F. Emerging roles for semaphorins and VEGFs in synaptogenesis and synaptic plasticity. Cell Adhesion & Migration 2012, 6:541-546.
59. Gitler A.D., Lu M.M., Epstein J.A. PlexinD1 and semaphorin signaling are required in endothelial cells for cardiovascular development. Developmental Cell 2004, 7:107-116.
60. Appleton B.A., Wu P., Maloney J., Yin J., Liang W.C., Stawicki S., et al. Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding. The EMBO Journal 2007, 26:4902-4912.
61. Gu C., Yoshida Y., Livet J., Reimert D.V., Mann F., Merte J., et al. Semaphorin 3E and plexin-D1 control vascular pattern independently of neuropilins. Science 2005, 307:265-268.
62. Acevedo L.M., Barillas S., Weis S.M., Gothert J.R., Cheresh D.A. Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood 2008, 111:2674-2680.
63. Zacchigna S., Pattarini L., Zentilin L., Moimas S., Carrer A., Sinigaglia M., et al. Bone marrow cells recruited through the neuropilin-1 receptor promote arterial formation at the sites of adult neoangiogenesis in mice. The Journal of Clinical Investigation 2008, 118:2062-2075.
64. Fukushima Y., Okada M., Kataoka H., Hirashima M., Yoshida Y., Mann F., et al. Sema3E-PlexinD1 signaling selectively suppresses disoriented angiogenesis in ischemic retinopathy in mice. The Journal of Clinical Investigation 2011, 121:1974-1985.
65. Toyofuku T., Yoshida J., Sugimoto T., Yamamoto M., Makino N., Takamatsu H., et al. Repulsive and attractive semaphorins cooperate to direct the navigation of cardiac neural crest cells. Developmental Biology 2008, 321:251-262.
66. Feiner L., Webber A.L., Brown C.B., Lu M.M., Jia L., Feinstein P., et al. Targeted disruption of semaphorin 3C leads to persistent truncus arteriosus and aortic arch interruption. Development 2001, 128:3061-3070.
67. Brown C.B., Feiner L., Lu M.M., Li J., Ma X., Webber A.L., et al. PlexinA2 and semaphorin signaling during cardiac neural crest development. Development 2001, 128:3071-3080.
68. Stalmans I., Lambrechts D., De Smet F., Jansen S., Wang J., Maity S., et al. VEGF: a modifier of the del22q11 (DiGeorge) syndrome. Nature Medicine 2003, 9:173-182.
69. Ruhrberg C., Schwarz Q. In the beginning: generating neural crest cell diversity. Cell Adhesion & Migration 2010, 4:622-630.
70. Schwarz Q., Maden C.H., Vieira J.M., Ruhrberg C. Neuropilin 1 signaling guides neural crest cells to coordinate pathway choice with cell specification. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:6164-6169.
71. Gammill L.S., Gonzalez C., Bronner-Fraser M. Neuropilin 2/semaphorin 3F signaling is essential for cranial neural crest migration and trigeminal ganglion condensation. Developmental Neurobiology 2007, 67:47-56.
72. Gammill L.S., Gonzalez C., Gu C., Bronner-Fraser M. Guidance of trunk neural crest migration requires neuropilin 2/semaphorin 3F signaling. Development 2006, 133:99-106.
73. Maden C.H., Gomes J., Schwarz Q., Davidson K., Tinker A., Ruhrberg C. NRP1 and NRP2 cooperate to regulate gangliogenesis, axon guidance and target innervation in the sympathetic nervous system. Developmental Biology 2012, 369:277-285.
74. Schwarz Q., Vieira J.M., Howard B., Eickholt B.J., Ruhrberg C. Neuropilin 1 and 2 control cranial gangliogenesis and axon guidance through neural crest cells. Development 2008, 135:1605-1613.
75. Schwarz Q., Maden C.H., Davidson K., Ruhrberg C. Neuropilin-mediated neural crest cell guidance is essential to organise sensory neurons into segmented dorsal root ganglia. Development 2009, 136:1785-1789.
76. Roffers-Agarwal J., Gammill L.S. Neuropilin receptors guide distinct phases of sensory and motor neuronal segmentation. Development 2009, 136:1879-1888.
77. Waimey K.E., Huang P.H., Chen M., Cheng H.J. Plexin-A3 and plexin-A4 restrict the migration of sympathetic neurons but not their neural crest precursors. Developmental Biology 2008, 315:448-458.
78. Prud'homme G.J., Glinka Y. Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget 2012.
79. Pellet-Many C., Frankel P., Evans I.M., Herzog B., Junemann-Ramirez M., Zachary I.C. Neuropilin-1 mediates PDGF stimulation of vascular smooth muscle cell migration and signalling via p130Cas. Biochemical Journal 2011, 435:609-618.
80. Zhang S., Zhau H.E., Osunkoya A.O., Iqbal S., Yang X., Fan S., et al. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Molecular Cancer 2010, 9:9.
81. Sulpice E., Plouet J., Berge M., Allanic D., Tobelem G., Merkulova-Rainon T. Neuropilin-1 and neuropilin-2 act as coreceptors, potentiating proangiogenic activity. Blood 2008, 111:2036-2045.
82. Glinka Y., Prud'homme G.J. Neuropilin-1 is a receptor for transforming growth factor beta-1, activates its latent form, and promotes regulatory T cell activity. Journal of Leukocyte Biology 2008, 84:302-310.
83. Glinka Y., Stoilova S., Mohammed N., Prud'homme G.J. Neuropilin-1 exerts co-receptor function for TGF-beta-1 on the membrane of cancer cells and enhances responses to both latent and active TGF-beta. Carcinogenesis 2011, 32:613-621.
84. Fukasawa M., Matsushita A., Korc M. Neuropilin-1 interacts with integrin beta1 and modulates pancreatic cancer cell growth, survival and invasion. Cancer Biology and Therapy 2007, 6:1173-1180.
85. Serini G., Valdembri D., Zanivan S., Morterra G., Burkhardt C., Caccavari F., et al. Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function. Nature 2003, 424:391-397.
86. Valdembri D., Caswell P.T., Anderson K.I., Schwarz J.P., Konig I., Astanina E., et al. Neuropilin-1/GIPC1 signaling regulates alpha5beta1 integrin traffic and function in endothelial cells. PLoS Biology 2009, 7:e25.
87. Murga M., Fernandez-Capetillo O., Tosato G. Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood 2005, 105:1992-1999.
88. Shimizu M., Murakami Y., Suto F., Fujisawa H. Determination of cell adhesion sites of neuropilin-1. The Journal of Cell Biology 2000, 148:1283-1293.
89. Neufeld G., Sabag A.D., Rabinovicz N., Kessler O. Semaphorins in angiogenesis and tumor progression. Cold Spring Harbor Perspectives in Medicine 2012, 2:a006718.
90. Rehman M., Tamagnone L. Semaphorins in cancer: biological mechanisms and therapeutic approaches. Seminars in Cell & Developmental Biology 2012.
91. Yaqoob U., Cao S., Shergill U., Jagavelu K., Geng Z., Yin M., et al. Neuropilin-1 stimulates tumor growth by increasing fibronectin fibril assembly in the tumor microenvironment. Cancer Research 2012, 72:4047-4059.
92. Miao H.Q., Lee P., Lin H., Soker S., Klagsbrun M. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB Journal 2000, 14:2532-2539.
93. Jarvis A., Allerston C.K., Jia H., Herzog B., Garza-Garcia A., Winfield N., et al. Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction. Journal of Medicinal Chemistry 2010, 53:2215-2226.
94. Glinka Y., Mohammed N., Subramaniam V., Jothy S., Prud'homme G.J. Neuropilin-1 is expressed by breast cancer stem-like cells and is linked to NF-kappaB activation and tumor sphere formation. Biochemical and Biophysical Research Communications 2012, 425:775-780.
95. Bachelder R.E., Lipscomb E.A., Lin X., Wendt M.A., Chadborn N.H., Eickholt B.J., et al. Competing autocrine pathways involving alternative neuropilin-1 ligands regulate chemotaxis of carcinoma cells. Cancer Research 2003, 63:5230-5233.
96. Tamagnone L. Emerging role of semaphorins as major regulatory signals and potential therapeutic targets in cancer. Cancer Cell 2012, 22:145-152.
97. Muller M.W., Giese N.A., Swiercz J.M., Ceyhan G.O., Esposito I., Hinz U., et al. Association of axon guidance factor semaphorin 3A with poor outcome in pancreatic cancer. International Journal of Cancer 2007, 121:2421-2433.
98. Bagci T., Wu J.K., Pfannl R., Ilag L.L., Jay D.G. Autocrine semaphorin 3A signaling promotes glioblastoma dispersal. Oncogene 2009, 28:3537-3550.
99. Maione F., Molla F., Meda C., Latini R., Zentilin L., Giacca M., et al. Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. Journal of Clinical Investigation 2009, 119:3356-3372.
100. Drenberg C.D., Livingston S., Chen R., Kruk P.A., Nicosia S.V. Expression of semaphorin 3F and its receptors in epithelial ovarian cancer, fallopian tubes, and secondary mullerian tissues. Obstetrics and Gynecology International 2009, 2009:730739.
101. Joseph D., Ho S.M., Syed V. Hormonal regulation and distinct functions of semaphorin-3B and semaphorin-3F in ovarian cancer. Molecular Cancer Therapeutics 2010, 9:499-509.
102. Brambilla E., Constantin B., Drabkin H., Roche J. Semaphorin SEMA3F localization in malignant human lung and cell lines: a suggested role in cell adhesion and cell migration. The American Journal of Pathology 2000, 156:939-950.
103. Futamura M., Kamino H., Miyamoto Y., Kitamura N., Nakamura Y., Ohnishi S., et al. Possible role of semaphorin 3F, a candidate tumor suppressor gene at 3p21.3, in p53-regulated tumor angiogenesis suppression. Cancer Research 2007, 67:1451-1460.
104. Xiang R., Davalos A.R., Hensel C.H., Zhou X.J., Tse C., Naylor S.L. Semaphorin 3F gene from human 3p21.3 suppresses tumor formation in nude mice. Cancer Research 2002, 62:2637-2643.
105. Bielenberg D.R., Hida Y., Shimizu A., Kaipainen A., Kreuter M., Kim C.C., et al. Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. The Journal of Clinical Investigation 2004, 114:1260-1271.
106. Coma S., Shimizu A., Klagsbrun M. Hypoxia induces tumor and endothelial cell migration in a semaphorin 3F- and VEGF-dependent manner via transcriptional repression of their common receptor neuropilin 2. Cell Adhesion & Migration 2011, 5:266-275.
107. Kusy S., Nasarre P., Chan D., Potiron V., Meyronet D., Gemmill R.M., et al. Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells. Neoplasia 2005, 7:457-465.
108. Potiron V.A., Sharma G., Nasarre P., Clarhaut J.A., Augustin H.G., Gemmill R.M., et al. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer Research 2007, 67:8708-8715.
109. Pan Q., Chanthery Y., Liang W.C., Stawicki S., Mak J., Rathore N., et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 2007, 11:53-67.